Achieving clinical and commercial success in the anti-obesity market

In this week's Expert View, Tobias Handschuh and Clemens Freytag from Oliver Wyman’s health and life sciences division provide insight into the strategic imperatives drugmakers must embrace if they are to compete in the obesity space.

Obesity is one of the most urgent health challenges of our time. With more than half the global population estimated to be either overweight or living with obesity in the next 12 years and the cost of the condition is predicted to soar to  $4.3 trillion, there is no question that innovative weight loss solutions will significantly contribute to the sustainability of the healthcare sector.

Having effective therapeutic options for weight has long been one of the most important underserved needs in the obesity space.